Clinical Trial

Anti-HER2 CAR-T Cell Injection in Patients With HER2-positive Advanced Malignant Solid Tumors

Recruiting
View on ClinicalTrials.gov →
Summary
This is a single-arm, open-label, exploratory clinical study to evaluate the safety and preliminary efficacy of Anti-HER2 CAR-T cell injection in patients with HER2-positive advanced malignant solid tumors.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-10-23; most recent amendment 2026-03-18.
Status change: Not Yet Recruiting → Recruiting 2025-04-14
Trial Details
NCT Number NCT06658951
Lead Sponsor UTC Therapeutics Inc.
Collaborators: The First Affiliated Hospital of Zhengzhou University
Conditions HER2-positive Advanced Malignant Solid Tumors
Enrollment 30 participants
Start Date 2025-04-03
Primary Completion 2027-04-30 (estimated)
Study Completion 2028-04-30 (estimated)
Updated on ClinicalTrials.gov 2026-03-19